Month: February 2022

Actuate Therapeutics Announces Initiation of a Multicenter Randomized Trial of Elraglusib Plus FOLFIRINOX As First Line Therapy for Advanced Pancreatic Cancer

Elraglusib will be combined with FOLFIRINOX alone or with Losartan in multi-center Phase 2 clinical study initiated at Massachusetts General...

error: Content is protected !!